Investigative biotech and pharma news source BioPharm Insight recently quoted Dr. Randy Vogenberg in a piece on ovarian cancer drug Zejula (niraparib), its pricing strategy, and potential payers’ reaction. Dr. Vogenberg is a principle at Institute for Integrated Healthcare and founding partner of NICH.
Many experts say the recently FDA-approved drug may face additional scrutiny for longer durations of the treatment, even though the published price for Zejula should be viewed as reasonable to payers.
See Dr. Vogenberg’s views on the dose that is likely to remain reimbursed by payers and his thoughts on concerns around potential risks to the drug’s adherence. Download the full BioPharm Insight article ‘Tesaro’s Zejula pricing deemed reasonable for payers, but longer use may result in more scrutiny for ovarian cancer maintenance’ here.
Be sure to visit BioPharm Insight’s website for further comprehensive life sciences investigative journalism and analytics.